Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18497935 | 0.79 | KDM4E (0.31) | KDM4E | |
| SCHEMBL25280025 | 0.79 | WNT1 (0.35) | KDM1A | |
| SCHEMBL18655858 | 0.78 | CTSK (0.42) | EPHX1EPHX2HSD11B1 | |
| SCHEMBL27080337 | 0.76 | KDM1A (0.41) | EPHX1EPHX2KDM1ASMN1; SMN2 | |
| SCHEMBL24220995 | 0.76 | CYP2C19 (0.54) | KDM4EHSD11B1SMN1; SMN2 | |
| SCHEMBL17624485 | 0.75 | TSHR (0.32) | — | |
| SCHEMBL19430972 | 0.74 | KDM1A (0.32) | KDM1A | |
| SCHEMBL19431095 | 0.73 | ADH1B (0.37) | — | |
| SCHEMBL15751172 | 0.72 | CYP2C19 (0.35) | — | |
| SCHEMBL27761713 | 0.72 | EPHX2 (0.54) | EPHX1EPHX2KDM4ESMN1; SMN2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167283-B2 | β-lactamase inhibitors and uses thereof | SUANZHU PHARMA CO., LTD. (CN) | 2019-01-01 | — | — | US | disclosed |
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| EP-3281942-A1 | B-LACTAMASE INHIBITOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2018-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167283-B2 | β-lactamase inhibitors and uses thereof | MGAM, LCT, ALPI | EPHX1 1040/4885EPHX2 916/4885KDM4E 918/4885 |
| US-20180148448-A1 | ß-LACTAMASE INHIBITORS AND USES THEREOF | MGAM, LCT, ALPI | EPHX1 1018/4885EPHX2 881/4885KDM4E 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.